p to one million plant and animal species face extinction, many within decades, because of human activities, says the most comprehensive report yet on the state of global ecosystems.
The rate of species extinctions is already tens to hundreds of times higher than the average across the past ten million years. Without drastic action to conserve habitats, the extinction rate will only increase, says a United Nationsbacked panel called the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES).
About 75% of land and 66% of ocean areas have been "significantly altered" by people, driven in large part by agriculture, according to a summary of the work, released on 6 May (see go.nature.com/2v4zbn9). The loss of species and habitats poses as much a danger to life on Earth as climate change does, the IPBES report says.
The analysis distils findings from nearly 15,000 studies and government reports, integrating information from the natural and social sciences, Indigenous peoples and traditional agricultural communities. The report is the first major international appraisal of biodiversity since 2005. Representatives of 132 governments met last week in Paris to finalize and approve it.
"We have never had a single unified statement from the world's governments that unambiguously makes clear the crisis we are facing for life on Earth, " says Thomas Brooks, chief scientist at the International Union for Conservation of Nature in Gland, Switzerland, who helped to edit the report. "That is really the absolutely key novelty that we see here. "
Without "transformative changes" to the world's economic, social and political systems to address this crisis, the IPBES panel projects that major biodiversity losses will continue to 2050 and beyond.
The analysis, which will be released in full later this year, also inextricably links biodiversity loss and climate change. An estimated 5% of all species would be threatened with extinction by 2 °C of warming above pre-industrial levels -a threshold that the world could breach in the next few decades, unless greenhouse-gas emissions are drastically reduced.
The biodiversity crisis should be at the top of the global agenda alongside climate, said Anne Larigauderie, IPBES executive secretary, at a 6 May press conference in Paris. "We can no longer say that we did not know, " she said.
Brooks says that the IPBES report will help to set the agenda when governments negotiate conservation goals for the next decade at the UN Convention on Biodiversity next year. ■ But the excitement around cancer immuno therapies -two researchers won a Nobel prize last year for pioneering them -has been tempered after several participants in US clinical trials died from side effects. Regulators around the world have moved slowly to approve the treatments for sale. The US Food and Drug Administration has approved only three cancer immunotherapies so far, and the Chinese drug regulator has approved none.
Before 2016, Chinese regulations for the sale of cell therapies were ambiguous, and many hospitals sold the treatments to patients while safety and efficacy testing was still under way. Ren Jun, an oncologist at the Beijing Shijitan Hospital Cancer Center, estimates that roughly one million people paid for such procedures.
But the market came under scrutiny when it was revealed that a university student with a rare cancer had paid more than 200,000 yuan (US$30,000) for an experimental immunotherapy, after seeing it promoted by a hospital on the Internet. The treatment was unsuccessful, and the student later died. The government cracked down on hospitals selling cell therapies -although clinical trials in which participants do not pay for treatment were allowed to continue.
GATHERING EVIDENCE
Under the proposed regulations, roughly 1,400 elite hospitals that conduct medical research, known as Grade 3A hospitals, would be able to apply for a licence to sell cell therapies, after proving that they have expertise in processing the cells and running clinical trials.
Once the hospital was licensed, its review board would oversee clinical research of experimental therapies, with participants who did not pay. If the board were to decide that these investigations had produced enough evidence that a therapy was safe and effective, the hospital would be able to start selling it.
Ren is confident that the measures would prevent treatments of unknown quality being promoted and sold.
But not everyone agrees. "The proposed regulation is a bad idea," says Michele Teng, who studies cancer immunotherapy at QIMR Berghofer. "It is critical that any new cellular therapy to be administered into patients demonstrates its safety and efficacy in phase III efficacy trials. "
Having large, well-funded facilities and trained medical staff is not an adequate substitute for well-designed studies to determine whether a treatment is efficacious or not, says Douglas Sipp, who studies cell-therapy policies at the RIKEN Center for Biosystems Dynamics Research in Kobe, Japan.
The rules could even dissuade companies from doing rigorous studies, he says. ■ Habitats such as coral reefs have been hit hard by pollution and climate change.
